Murdoch D L, Gillen G J, Morton J J, Leckie B, Murray G D, Davies D L, McInnes G T
University Department of Medicine, Western Infirmary, Glasgow, UK.
J Hum Hypertens. 1989 Feb;3(1):29-33.
Twice-daily captopril (25 mg) and placebo were compared in ten hypertensive patients who were already receiving bendrofluazide. After six weeks therapy, captopril produced significant antihypertensive effects one to six hours after dosing but these did not persist at eleven to twelve hours. Plasma renin concentration was increased for twelve hours after captopril but inhibition of angiotensin II activity was lost by twelve hours. During the period when captopril reduced blood pressure significantly, effective renal plasma flow and hepatic blood flow were unchanged although renal vascular resistance was reduced. There was no evidence that captopril altered plasma sodium, potassium or magnesium concentrations following bendrofluazide. Thus, in thiazide-treated patients, captopril 25 mg produces significant blood pressure reduction for at least six hours after dosing, without impairing renal or hepatic blood flow. However, twice-daily low-dose captopril does not adequately control blood pressure throughout the dosage interval.
在10名已接受苄氟噻嗪治疗的高血压患者中,对每日两次服用卡托普利(25毫克)和安慰剂进行了比较。经过六周的治疗,卡托普利在给药后1至6小时产生显著的降压作用,但在11至12小时时这些作用不再持续。卡托普利给药后12小时内血浆肾素浓度升高,但12小时后血管紧张素II活性的抑制作用消失。在卡托普利显著降低血压的期间,尽管肾血管阻力降低,但有效肾血浆流量和肝血流量未发生变化。没有证据表明卡托普利会改变苄氟噻嗪治疗后的血浆钠、钾或镁浓度。因此,在接受噻嗪类治疗的患者中,25毫克卡托普利给药后至少6小时能显著降低血压,且不损害肾或肝血流量。然而,每日两次的低剂量卡托普利在整个给药间隔内不能充分控制血压。